Login / Signup

Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B.

Chan-Young JungHyung Woo KimSang Hoon AhnSeung-Up KimBeom Seok Kim
Published in: Liver international : official journal of the International Association for the Study of the Liver (2022)
ETV was associated with a higher risk of kidney function decline than TAF in patients with treatment-naïve CHB. Therefore, further prospective randomized studies are needed.
Keyphrases
  • hepatitis b virus
  • double blind
  • open label
  • acute lymphoblastic leukemia
  • placebo controlled
  • antiretroviral therapy
  • phase ii
  • study protocol
  • liver fibrosis